EMA's trial design hinders Eisai's Halaven reimbursement in Germany
This article was originally published in Scrip
Executive Summary
Eisai's end of life breast cancer drug Halaven (eribulin) offers a "hint" of "unquantifiable" additional benefit against comparators for patients unable to continue treatment with taxanes or anthracyclines, according to a preliminary benefit assessment by the German health technology appraisal body, IQWiG. Furthermore, the drug offers no additional benefit for patients able to continue with taxanes or anthracyclines, said the institute.